NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Relmada Therapeutics, Inc. (RLMD) Stock Analysis

Relmada Therapeutics, Inc. (RLMD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

RLMD

$3.21

−$0.15 (−4.46%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RLMD with… →

RLMD Key Statistics

As of Oct 21, 2026
Trading
Open
$3.35
Previous Close
$3.36
Day's Range
3.19–3.40
52-Week Range
1.98–8.00
Volume
1.72M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.51
Valuation
Market Cap
$342.41M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.91
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$57.39M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
106.67M
1-Year Return
+43.30%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
1.24M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, RLMD closed at $3.21, +43.30% over 1 year.

Relmada Therapeutics, Inc. (RLMD) has a market capitalization of $342.41M.

In fiscal 2025, RLMD reported revenue of $0.00.

RLMD Stock Return by Calendar Year

Relmada Therapeutics, Inc. (RLMD) 10-year return: what $10,000 became

1 year
$10,000 $14,330
+43.30%
5 years
$10,000 $1,359
−86.41%
10 years
$10,000 $8,025
−19.75%

If you had invested $10,000 in Relmada Therapeutics, Inc. (RLMD) 10 years ago, at the close on October 21, 2016, it would have been worth $8,025 at the close on October 21, 2026: −19.75% in total, −2.18% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−33.54%
2025+828.85%
2024−87.44%
2023+18.62%
2022−84.51%
2021−29.75%
2020−17.77%
2019+747.83%
2018+53.33%
2017−31.19%
2016 (partial year)−31.01%

As of October 21, 2026.

RLMD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$57.39M—
2024$0.00−$79.98M—
2023$0.00−$98.79M—
2022$0.00−$157.04M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$59.10M−$57.39M—
2024$0.00—−$83.89M−$79.98M—
2023$0.00—−$103.70M−$98.79M—
2022$0.00—−$161.25M−$157.04M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Relmada Therapeutics, Inc. (RLMD) is capitalised at $342.41M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 17 employees.

The 52-week range on file runs from $1.98 to $8.00. The most recent close on file for RLMD is $3.21, dated October 21, 2026. That is −$0.15 (−4.46%) against the previous close. The latest close sits 62.12% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $57.39M. Earnings per share on a trailing basis come to −0.91.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 0.51. Annualized volatility over the trailing 10 years is 113.28%. The trailing one-year total return is +43.30%. Across 10 years the annualized return works out at −2.18%.

Growth & Income

No dividend is on file for RLMD.

2026 is still running; the total return is −33.54% year to date. Across the complete calendar years on file, 2025 returned +828.85% and 2024 returned −87.44%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Relmada Therapeutics, Inc. (RLMD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Relmada Therapeutics, Inc. RLMD $342.41M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Relmada Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Visit website →